ReviewFood science & nutrition2026
Modulating the Gut-Ovarian Axis: Mechanistic Rationale and the Limits of Current Evidence for Probiotics in Female Reproductive Aging.
Review in Food science & nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Female reproductive aging is characterized by progressive follicular depletion, deterioration of oocyte quality, and endocrine decline, with oxidative stress, mitochondrial dysfunction, immune-inflammatory remodeling, and granulosa-cell loss contributing to ovarian functional deterioration. This critical narrative review, supported by a structured literature search, evaluates mechanistic, preclinical, and human evidence for probiotic and microbiota-targeted modulation of the gut-ovarian axis. The current evidence base remains predominantly preclinical. In premature ovarian insufficiency (POI), polycystic ovary syndrome (PCOS), chemotherapy-induced ovarian injury, and reproductive-aging models, selected interventions have modified intestinal microbial ecology, barrier function, microbial metabolites, and systemic immune-metabolic-endocrine signaling, with model-specific effects on ovarian redox homeostasis, granulosa-cell survival, follicular development, mitochondrial function, and oocyte-related outcomes. Mechanistic support is strongest where gut dependency, metabolite supplementation, or related causal approaches have been demonstrated, but responses remain highly strain-, model-, dose-, route-, and host-dependent. Human trials in PCOS and menopause-related or reproductive settings have reported changes in selected metabolic, hormonal, menstrual, symptom, quality-of-life, and fertility-related outcomes; however, our structured literature and trial-registry searches did not identify a randomized human trial specifically designed to test whether probiotic or microbiota-targeted intervention slows the longitudinal physiological loss of ovarian reserve or delays physiological ovarian aging. Findings from disease models, fecal microbiota transplantation, or other experimental interventions should therefore not be equated with the efficacy of oral probiotic foods or supplements. Current evidence supports biological plausibility and translational potential rather than established ovarian anti-aging efficacy. Future studies should evaluate well-characterized oral strains using prespecified ovarian-aging-relevant endpoints, mechanistic biomarkers, and standardized safety assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.